The manufacturer received information alleging a bipap device's sound abatement foam became degraded and caused lung, liver and kidney issues, difficulty breathing and fluid in the lungs.The patient did receive medical intervention and reported to have been hospitalized.This issue was reported to the fda per 21 cfr 806.The device will be corrected per res 88058.
|
The manufacturer received information alleging a bipap device's sound abatement foam became degraded and caused lung, liver and kidney issues, difficulty breathing and fluid in the lungs.The patient did receive medical intervention and reported to have been hospitalized.The device was returned to the manufacturer's product investigation laboratory for investigation.An internal visual inspection of the device was completed by the manufacturer.The manufacturer found evidence of an unknown dust contaminant and an unknown dark contaminant on the front panel, an unknown dark contaminant was on the blower box, an unknown contaminant was on the blower, consistent with liquid ingress, an unknown dust contaminant on the blower seal, a dark unknown contaminant on the rear panel, and an unknown contaminant on the bottom enclosure, a keratin-like substance on the blower box outlet.The manufacturer also found evidence of liquid ingress on the blower after removing it from the blower box, along with liquid ingress to the blower box.The manufacturer found no evidence of sound abatement foam degradation/breakdown.The device's event logs were downloaded and reviewed.The manufacturer found instances of e-22 and e-200.The manufacturer concludes there was evidence multiple contamination on the device.The manufacturer confirmed there was no evidence of sound abatement foam degradation/breakdown.After further review, the manufacturer confirmed that the previously submitted report was incorrectly filed as adverse event which should have been filed as product problem only.Section b1, b2, d9, g3 and h6 has been updated/corrected in this report.
|